This inventor holds 32 USPTO granted patents and 8 published patent applications, plus 6 CIPO patents and 8 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Infinity Pharmaceuticals, Inc., Infinity Discovery, Inc., Twelve Therapeutics, Inc.. Active years: 2010-2025.
Company Filing History:
28 out of 108 
3 out of 12 
1 out of 1 Years Active: 2010-2025
Areas of Expertise:
Title: **The Innovative Mind of Andre Lescarbeau: A Pioneer in Kinase Modulation**
Introduction
Andre Lescarbeau, based in Somerville, MA, has made significant contributions to the field of pharmaceuticals, holding an impressive portfolio of 31 patents. His innovative work primarily focuses on compounds that modulate kinase activity, shedding light on their potential uses in treating various diseases.
Latest Patents
Among his latest patents are "Heterocyclic Compounds and Uses Thereof" and "Solid Forms of Isoquinolinones, and Process of Making, Composition Comprising, and Methods of Using the Same." The first patent describes pharmaceutical compositions that can modulate kinase activity, particularly PI3 kinase, and provides methods for treating conditions linked to these pathways. The second patent discusses solid forms of chemical compounds and outlines processes to prepare and utilize these compounds effectively.
Career Highlights
Throughout his career, Andre Lescarbeau has worked with notable companies, including Infinity Pharmaceuticals, Inc. and Infinity Discovery, Inc. His experience in these innovative environments has enabled him to contribute to significant advancements in drug discovery and development.
Collaborations
Lescarbeau has collaborated with esteemed colleagues such as Martin R Tremblay and Alfredo C Castro. These partnerships have facilitated the exchange of ideas and propelled forward multiple research initiatives within the realm of kinase modulation.
Conclusion
Andre Lescarbeau is a remarkable inventor whose work continues to influence the pharmaceutical landscape. His extensive patent portfolio highlights his expertise and commitment to developing therapeutic solutions that target kinase activity, paving the way for advancements in the treatment of various conditions.